Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

IPO/Stock Watch

Market trends, bell-weather stocks, filings and IPOs...

Tigermed, a China Clinical CRO, Seeks up to $1 Billion in Hong Kong IPO

Sunshine Guojian, a 3SBio Subsidiary, Plans $248 Million Shanghai STAR Board IPO

Junshi Bio Stages $692 Million IPO on Shanghai's STAR Board

Gland Pharma, a Fosun Subsidiary, Plans $650 Million IPO in India

Ocumension Stages $184 Million HK IPO; Climbs 152% on First Day

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China